Neos Therapeutics

$0.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0047 (-0.81%) Today
-$0.0043 (-0.75%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NEOS and other stocks, options, and ETFs commission-free!

About NEOS

Neos Therapeutics, Inc. Common Stock, also called Neos Therapeutics, is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. The listed name for NEOS is Neos Therapeutics, Inc. Common Stock.

CEO
Gerald W. McLaughlin
Employees
213
Headquarters
Grand Prairie, Texas
Founded
1994
Market Cap
28.58M
Price-Earnings Ratio
Dividend Yield
Average Volume
461.75K
High Today
$0.59
Low Today
$0.562
Open Price
$0.59
Volume
277.37K
52 Week High
$1.98
52 Week Low
$0.4501

Collections

NEOS Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, Pre-Market

You May Also Like